Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001567619-23-004270 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-02 | 2023-02-28+ | ARQT | Burrows Scott L | CFO | S - Sale | $15.91 | -1,850 | 39.8K | -4% | -$29.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | S | D | 1,416 | $15.82 | 38,424 | D | — | — | (F3) The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-03-02 | S | D | 18 | $16.52 | 38,406 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-28 | S | D | 416 | $16.17 | 39,840 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |